Overall Score

Growth Durability

Gross margin remains very high at 88.1%, supporting strong product economics.

Revenue quality is still constrained by weak profitability, with net margin at -13.2% and operating margin at -13.5%.

Working capital intensity remains elevated, with a 402.3-day operating cycle and 381.7-day cash conversion cycle.

Financial Strength

Liquidity remains solid with a current ratio of 2.08 and quick ratio of 1.84.

Balance sheet leverage remains low, with debt-to-equity at 0.04 and debt-to-assets at 0.03.

Cash generation is still weak relative to sales, with operating cash flow margin at 2.4% and free cash flow yield at 0.7%.

Profitability Trend

Returns remain negative, with ROE at -10.4% and ROIC at -9.1%.

EBIT margin is still negative at -14.2%, indicating the business has not yet reached durable operating profitability.

Interest coverage remains strong, but this is offset by negative operating earnings.

Valuation

The stock trades at an EV/Sales multiple of 3.08, which is reasonable for a growth-oriented specialty pharma name.

Price-to-book is 2.62, reflecting a moderate valuation relative to equity book value.

Very weak free cash flow conversion keeps valuation support limited despite low leverage.